Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thyroid dermopathy responds to teprotumumab therapy.
Crespo-Trevino R, Schiffman J, Ugradar S, Cockerham K, Douglas R, de Leon-Garza D, Tang R. Crespo-Trevino R, et al. Among authors: ugradar s. Endocrinol Diabetes Metab Case Rep. 2022 Mar 1;2022:21-0201. doi: 10.1530/EDM-21-0201. Online ahead of print. Endocrinol Diabetes Metab Case Rep. 2022. PMID: 35319490 Free PMC article.
Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas R. Ugradar S, et al. Br J Ophthalmol. 2022 Jun;106(6):755-759. doi: 10.1136/bjophthalmol-2020-318314. Epub 2021 Feb 12. Br J Ophthalmol. 2022. PMID: 33579690 Free PMC article. Clinical Trial.
Teprotumumab for the treatment of chronic thyroid eye disease.
Ugradar S, Kang J, Kossler AL, Zimmerman E, Braun J, Harrison AR, Bose S, Cockerham K, Douglas RS. Ugradar S, et al. Eye (Lond). 2022 Aug;36(8):1553-1559. doi: 10.1038/s41433-021-01593-z. Epub 2021 Jul 9. Eye (Lond). 2022. PMID: 34244669 Free PMC article.
Teprotumumab for Asymmetric Thyroid Eye Disease.
Ugradar S, Wang Y, Douglas R. Ugradar S, et al. Ophthalmology. 2021 Oct;128(10):1416. doi: 10.1016/j.ophtha.2021.03.004. Ophthalmology. 2021. PMID: 34556309 No abstract available.
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Among authors: ugradar s. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C. Douglas RS, et al. Among authors: ugradar s. JAMA Ophthalmol. 2022 Apr 1;140(4):328-335. doi: 10.1001/jamaophthalmol.2021.6284. JAMA Ophthalmol. 2022. PMID: 35175308 Free PMC article.
70 results